Cargando…
Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer
AIM: This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). METHODS: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049748/ https://www.ncbi.nlm.nih.gov/pubmed/32161497 http://dx.doi.org/10.2147/CMAR.S237073 |
_version_ | 1783502505385132032 |
---|---|
author | Khalafi-Nezhad, Abolfazl Ebrahimi, Vahid Ahmadpour, Fatemeh Momtahan, Mozhdeh Robati, Minoo Saraf, Zahra Ramzi, Mani Jowkar, Zahra Ghaffari, Parvin |
author_facet | Khalafi-Nezhad, Abolfazl Ebrahimi, Vahid Ahmadpour, Fatemeh Momtahan, Mozhdeh Robati, Minoo Saraf, Zahra Ramzi, Mani Jowkar, Zahra Ghaffari, Parvin |
author_sort | Khalafi-Nezhad, Abolfazl |
collection | PubMed |
description | AIM: This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). METHODS: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. RESULTS: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2–5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. CONCLUSION: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients. |
format | Online Article Text |
id | pubmed-7049748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70497482020-03-11 Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer Khalafi-Nezhad, Abolfazl Ebrahimi, Vahid Ahmadpour, Fatemeh Momtahan, Mozhdeh Robati, Minoo Saraf, Zahra Ramzi, Mani Jowkar, Zahra Ghaffari, Parvin Cancer Manag Res Original Research AIM: This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). METHODS: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. RESULTS: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2–5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. CONCLUSION: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients. Dove 2020-02-26 /pmc/articles/PMC7049748/ /pubmed/32161497 http://dx.doi.org/10.2147/CMAR.S237073 Text en © 2020 Khalafi-Nezhad et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Khalafi-Nezhad, Abolfazl Ebrahimi, Vahid Ahmadpour, Fatemeh Momtahan, Mozhdeh Robati, Minoo Saraf, Zahra Ramzi, Mani Jowkar, Zahra Ghaffari, Parvin Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer |
title | Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer |
title_full | Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer |
title_fullStr | Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer |
title_full_unstemmed | Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer |
title_short | Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer |
title_sort | parity as a prognostic factor in patients with advanced-stage epithelial ovarian cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049748/ https://www.ncbi.nlm.nih.gov/pubmed/32161497 http://dx.doi.org/10.2147/CMAR.S237073 |
work_keys_str_mv | AT khalafinezhadabolfazl parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT ebrahimivahid parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT ahmadpourfatemeh parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT momtahanmozhdeh parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT robatiminoo parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT sarafzahra parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT ramzimani parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT jowkarzahra parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer AT ghaffariparvin parityasaprognosticfactorinpatientswithadvancedstageepithelialovariancancer |